Study links early menopause to diabetes risk, reduced life expectancy | Nutrition therapy tied to improved outcomes with gestational diabetes | Herpes may increase odds of Alzheimer's disease
October 22, 2018
AANP SmartBrief
News for nurse practitioners
SIGN UP ⋅   FORWARD
Health Care News
Study links early menopause to diabetes risk, reduced life expectancy
Researchers working with data from 3,650 postmenopausal women in the Netherlands found those with and without type 2 diabetes at baseline who experienced early menopause had higher mortality risk, compared with those who experienced normal and late menopause. The findings in Menopause showed that a "higher risk of diabetes in women with early age at natural menopause might reflect an earlier diagnosis of diabetes across the life span, and therefore a decreased life expectancy without [type 2 diabetes], although the difference in years lived overall and without [type 2 diabetes] did not differ significantly," researchers said.
Healio (free registration)/Endocrine Today (10/19) 
LinkedIn Twitter Facebook Google+ Email
Nutrition therapy tied to improved outcomes with gestational diabetes
Pregnant women with gestational diabetes had an improved glycemic profile that was comparable to pregnant women with normal glucose tolerance after following a Mediterranean diet-based medical nutrition therapy for three months, according to a study published in BMJ Open Diabetes Research & Care. The Spanish researchers also found those with gestational diabetes were at an increased risk for insufficient weight gain, infants born small for gestational age and urinary tract infections, compared with women without the condition.
Healio (free registration)/Endocrine Today (10/19) 
LinkedIn Twitter Facebook Google+ Email
Herpes may increase odds of Alzheimer's disease
People with the herpes simplex virus 1 in the brain, especially those with the APOE4 allele, were more likely to develop Alzheimer's disease, compared with those without either factor, according to a review in the Frontiers in Aging Neuroscience. The findings also showed that antiviral treatments significantly reduced the number of those with HSV1 who developed Alzheimer's, but that result may be due to better overall treatment among those patients, said researcher Ruth Itzhaki.
HealthDay News (10/19),  Medscape (free registration) (10/19) 
LinkedIn Twitter Facebook Google+ Email
Study ties pediatric asthma risk to infants' bilirubin levels
Babies with total serum bilirubin levels of 9 mg/dl to 17.9 mg/dl were significantly more likely to develop asthma, compared with those whose levels were 3 mg/dl to 5.9 mg/dl. The study in Pediatrics, based on data for 109,212 infants, found that levels of 18 mg/dl or higher weren't associated with increased asthma risk.
Pulmonology Advisor (10/19) 
LinkedIn Twitter Facebook Google+ Email
Earn a free subscription to The New York Times
Enjoying your SmartBrief? Why not share it with your network? Simply copy and share your personal referral link below. Once you refer five new subscribers, we'll send you a redemption code for your complimentary one-year access to The Times.
Your Referral Link: smartbrief.com/AANP/?referrerId=eSriBJbAIQ
ADVERTISEMENT
Pharmaceutical News
Regeneron, Sanofi's Dupixent approved for asthma
Regeneron, Sanofi's Dupixent approved for asthma
(Eric Piermont/AFP/Getty Images)
Regeneron Pharmaceuticals and Sanofi's Dupixent, or dupilumab, was approved by the FDA as an add-on maintenance treatment for patients age 12 and older who have an eosinophilic phenotype or oral corticosteroid-dependent moderate to severe asthma. The drug was previously approved for eczema.
Seeking Alpha (10/20) 
LinkedIn Twitter Facebook Google+ Email
 
Genentech's Rituxan gets FDA nod for new indications
Roche Holding unit Genentech's Rituxan, or rituximab, was granted FDA approval as a treatment for adult patients with two rare forms of vasculitis -- microscopic polyangiitis and granulomatosis with polyangiitis -- who have achieved disease control using induction therapy.
Seeking Alpha (10/19) 
LinkedIn Twitter Facebook Google+ Email
Hot Topics
.
SPOTLIGHT ON POST-OP PAIN RELIEF
Sponsored content from Tylenol®
Most patients would choose a non-opioid
Based on a 2016, 500-person survey in patients who had orthopedic surgery, ~80% of patients would choose a non-opioid for post-op pain. The American Pain Society recommends acetaminophen (eg, TYLENOL®) as an effective analgesic option to include in a multimodal treatment plan.
 
LinkedIn Twitter Facebook Google+ 
Click here to learn more about Featured Content
Emerging Trends, Products and Technologies
Researchers look at youth use of Juul e-cigarettes
Nearly 16% of teens and young adults have used Juul e-cigarettes, compared with 30% who have used other e-cigarettes and 24% who have used traditional tobacco, according to a study in JAMA Network Open. Those using Juul e-cigarettes "were using them a significantly greater number of days, which gives us a concern whether they are addicted to those products," said senior researcher Bonnie Halpern-Felsher.
HealthDay News (10/19) 
LinkedIn Twitter Facebook Google+ Email
FDA OKs Abbott's HeartMate 3 for long-term destination therapy
The FDA has granted Abbott approval for its HeartMate 3 left-ventricular assist device as a long-term destination therapy in patients with advanced heart failure who are not likely to get a heart transplant. A 366-patient study this year showed 83% survival at two years, compared with 76% using its predecessor, HeartMate II.
Star Tribune (Minneapolis-St. Paul, Minn.) (tiered subscription model) (10/19) 
LinkedIn Twitter Facebook Google+ Email
AI-based tool shows promise in detecting DR, study finds
An artificial intelligence-based deep learning algorithm had a 97% sensitivity rating, 91.4% specificity and an area under the curve of .989 in detecting vision-threatening referable diabetic retinopathy, according to a study in Diabetes Care. Researchers evaluated 71,043 retinal images, with a panel of 21 ophthalmologists grading each image for diabetic retinopathy severity, and found that the tool "offers [the] potential to increase the efficiency and accessibility of [diabetic retinopathy] screening programs, particularly in developing countries ... and in minority and underserved populations."
Endocrinology Advisor (10/19) 
LinkedIn Twitter Facebook Google+ Email
Health Policy and Legislative News
Healthcare.gov system breach may have exposed info of 75K people
The CMS said it has detected a breach in a government computer system used by agents and brokers to assist consumers with health plan enrollment through the Affordable Care Act exchange, and it potentially exposed the personal information of roughly 75,000 individuals. The agency said the system has been disabled to implement new security measures and could be restored within seven days.
The Verge (10/20),  CNN (10/20) 
LinkedIn Twitter Facebook Google+ Email
AANP News
2018 National NP Sample Survey is Open!
AANP is currently conducting the eighth iteration of the National NP Sample Survey, which collects information to provide a national characterization of NPs. This data will be used to inform policymakers and other organizations or groups advocating for the NP profession. Almost 54,000 NPs were randomly selected to participate and were invited via email. Follow-up invitations will be sent out this coming week. If you receive an invitation, please consider participating! If you have any questions, please contact AANP by email at research@aanp.org or by phone at 512-442-4262.
LinkedIn Twitter Facebook Google+ Email
Learn more about AANP:
Home Page | Join AANP | Legislation/Practice
AANP JobCenter | AANP Store
  
  
The first principle is that you must not fool yourself -- and you are the easiest person to fool.
Richard Feynman,
theoretical physicist
LinkedIn Twitter Facebook Google+ Email
  
  
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Partner Relations Manager  -  Madeline Sarver
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information